spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Millennium Pharmaceuticals 

 HSMN NewsFeed - 17 Jul 2024
Alltrna Announces Updates to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Nov 2022
Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2020
Spirovant Sciences Appoints Roland Kolbeck, PhD, as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2020
West Elects New Director to the Board
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 2 Jul 2019
InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Feb 2019
Proteostasis Therapeutics Appoints Emmanuel Dulac and Kim Drapkin to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Jan 2019
Histogen Appoints Richard Pascoe as Chairman and Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 31 Jul 2017
Foresee Pharmaceuticals Announces CEO Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 May 2017
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta (γδ) T Cells
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2017
Mitra Appoints Anton Ehrhardt as Vice President of Medical Affairs
Diagnostics Oncology Personnel
 HSMN NewsFeed - 21 Nov 2016
Gamida Cell Names Julian Adams, Ph.D. New Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Nov 2016
Blueprint Medicines Announces Appointment of Marion Dorsch, Ph.D. as Chief Scientific Officer and the Transition of Christoph Lengauer, Ph.D., MBA, to a Newly Created Executive Vice President Role
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jul 2016
Decibel Therapeutics Appoints Steven H. Holtzman as President and Chief Executive Officer
Devices Personnel
 HSMN NewsFeed - 3 Nov 2015
Jounce Therapeutics Appoints Elizabeth Trehu, M.D., to Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Sep 2015
Jounce Therapeutics Appoints Kim Drapkin, CPA as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2015
Metamark Genetics Appoints Kenneth E. Weg as President and Chief Executive Officer
Diagnostics Oncology Personnel
 HSMN NewsFeed - 29 Jul 2015
Unum Therapeutics Names Geoffrey Hodge as Senior Vice President, Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jul 2015
KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 May 2015
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2015
Pain Therapeutics Announces Appointment of Senior Vice President, Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2015
Takeda Announces Appointment of New President of U.S. Business Unit
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Mar 2015
Mersana Raises $35 Million in Series B Financing and Appoints Anna Protopapas as President and Chief Executive Officer
Devices Drug Delivery Venture Capital Personnel
 HSMN NewsFeed - 22 Oct 2014
Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors
Diagnostics Personnel
 HSMN NewsFeed - 9 Jun 2014
Solstice Biologics Appoints Dr. Lou Tartaglia as President, Chief Executive Officer; John Borgeson Joins as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2014
ARIAD Announces Appointment of Hugh Cole, Senior Pharmaceutical-Industry Executive, as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Feb 2014
Ambrx Appoints Barry Greene to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jan 2014
Progenics Pharmaceuticals Announces the Appointment of Karen Ferrante, M.D. to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Dec 2013
Takeda Launches New Subsidiary in Israel
Biopharmaceuticals
 HSMN NewsFeed - 17 Dec 2013
Heat Biologics, Inc. Appoints Dr. Anil K. Goyal as Vice President of Business Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 30 Sep 2013
Alkermes Expands Senior Management Team
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 14 Aug 2013
SAGE Therapeutics Appoints Biotech Industry Veteran Dr. Jeffrey Jonas to Chief Executive Officer; Expands Leadership Team with Two Key Appointments
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 8 Aug 2013
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Jul 2013
Warp Drive Bio Appoints Co-Founder Gregory Verdine, Ph.D., to Chief Executive Officer; Expands Team with Two Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2013
Third Rock Ventures Expands and Strengthens Team
Biopharmaceuticals Devices Venture Capital Personnel
 HSMN NewsFeed - 21 Mar 2013
Takeda Launches New Subsidiary in Ecuador
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2013
NewLink Genetics Appoints Mr. Brian Wiley as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Oct 2012
Takeda and Millennium Announce European Conditional Marketing Authorization for ADCETRIS(R) (Brentuximab Vedotin)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2012
Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Mar 2012
Constellation Pharmaceuticals Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2012
Interwest Partners Expands Medical Devices Team
Devices Venture Capital Personnel
 HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2011
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Sep 2011
Eleven Biotherapeutics Appoints Abbie Celniker, Ph.D., Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2011
iPierian Appoints Nancy Stagliano as CEO; Peter Van Vlasselaer, Interim CEO, Becomes Executive Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Aug 2011
Selecta Biosciences Appoints Takashi Kei Kishimoto, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2011
SciFluor Life Sciences Appoints Life Sciences Executive Arthur Hiller as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 May 2011
Accumetrics Signs National Distribution Agreement with Cardinal Health
Diagnostics Personalized Medicine Cardiology Distribution
 HSMN NewsFeed - 12 Apr 2011
Portola Pharmaceuticals Appoints Dr. James Topper to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2011
Blueprint Medicines Secures $40 Million Series A Financing to Translate New Molecular Data into Personalized Cancer Treatments
Personalized Medicine Oncology Venture Capital
 HSMN NewsFeed - 9 Mar 2011
2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery
Diagnostics Biopharmaceuticals Surgery Cardiology
 HSMN NewsFeed - 1 Feb 2011
Constellation Pharmaceuticals Expands Leadership Team with Drug Development Industry Veterans
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jan 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Biogen Idec Appoints Doug Williams to Head R&D, Steven Holtzman to Head Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2010
Alnylam Elects Marsha Fanucci to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2010
GRAVITAS Trial Shows That a Uniform Treatment Strategy of Doubling the Standard Dose of Plavix Does Not Improve Outcomes Post-PCI
Diagnostics Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 8 Nov 2010
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Sep 2010
BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2010
Cubist Pharmaceuticals Announces Promotion of Steven C. Gilman, Ph.D., to EVP, Research and Development and Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2010
EpiCept Corporation Names Rita Kelley Senior Director of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2010
Alnylam Strengthens Management Team with New Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2010
Infinity Announces Senior Management Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 May 2010
Nuon Therapeutics Names Lee Rauch Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Apr 2010
Taligen Appoints Industry Leader, John Maraganore, as Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2010
Inadequate Response to Clopidogrel Leads to Higher Incidence of Major Adverse Cardiac Events in Patients Who have Undergone PCI
Biopharmaceuticals Diagnostics Cardiology
 HSMN NewsFeed - 11 Mar 2010
Portola Pharmaceuticals Announces Senior Management and Board Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2010
Constellation Pharmaceuticals Appoints Kerry K. Reinertsen, Ph.D. as Company's Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2010
Intuity Medical Closes $64 Million Series D Financing - One of the Largest Medical Device Funding Events of 2009
Devices Monitoring Endocrinology Venture Capital
 HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Dec 2009
Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late-Stage Lymphoma Program Brentuximab Vedotin (SGN-35)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2009
NeurogesX Expands Commercial Operations Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Oct 2009
Aileron Therapeutics Appoints Steven Kafka, Ph.D. as Company's First Chief Financial Officer and Vice President, Finance and Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Sep 2009
Steven Holtzman Joins Satori Pharmaceuticals' Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jul 2009
Cerulean Pharma Inc. Closes $10 Million Series B-1 Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 May 2009
Accumetrics, Inc. Announces European Distribution Channels for France, Austria, Switzerland, Netherlands, Belgium and Luxembourg
Diagnostics Cardiology Distribution
 HSMN NewsFeed - 27 May 2009
Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 May 2009
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 May 2009
Archemix Appoints Ken Bate as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2009
Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2009
RXi Pharmaceuticals Announces an Addition, Promotions Among Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Mar 2009
EPIX Pharmaceuticals Appoints Elkan Gamzu, Ph.D., as Permanent CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Feb 2009
Gregory J. Tibbitts Appointed Chief Financial Officer at Accumetrics, Inc.
Devices Diagnostics Personnel
 HSMN NewsFeed - 25 Feb 2009
Selecta Biosciences, Inc. Closes $15.1M Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Jan 2009
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 25 Nov 2008
Awarepoint Corporation Closes $13.3 M Series D Financing Round
Devices Venture Capital
 HSMN NewsFeed - 4 Nov 2008
Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
Diagnostics Cardiology Personnel
 HSMN NewsFeed - 30 Oct 2008
Timothy I. Still Appointed CEO at Accumetrics
Diagnostics Personnel
 HSMN NewsFeed - 14 Oct 2008
Surface Logix Appoints Keith Dionne as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2008
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2008
Microfabrica Secures $22.5 Million Funding to Grow Its Medical Device Business
Devices Venture Capital
 HSMN NewsFeed - 12 Aug 2008
Follica Announces $11M in New Financing and Expanded Team
Devices Personnel Venture Capital
 HSMN NewsFeed - 28 Jul 2008
EPIX Pharmaceuticals Announces Resignation of CEO; Names Elkan Gamzu Interim CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jun 2008
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 May 2008
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 May 2008
Takeda Completes Acquisition of Millennium
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 May 2008
Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Apr 2008
Takeda and Millennium Announce Early Termination of Hart-Scott-Rodino Waiting Period
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Apr 2008
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2008
Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Mar 2008
Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Mar 2008
Momenta Pharmaceuticals Appoints Dr. James M. Roach as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Feb 2008
Calistoga Pharmaceuticals Announces Appointment of R. Lee Douglas, 22-Year Biotechnology/Pharmaceutical Industry Veteran, to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2008
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Jan 2008
EyeGate Pharma Appoints Michael A. Patane to Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
Tempo Pharmaceuticals Closes $8 Million in Series B Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Jan 2008
Kosan Appoints Helen S. Kim as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2007
Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 14 Dec 2007
Alnylam Appoints Barry Greene President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2007
Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2007
BIND Biosciences, Inc. Closes $16M Series B Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Multiple Myeloma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2007
FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 18 Sep 2007
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Sep 2007
Third Rock Ventures Debuts with $378 Million Fund in Life Sciences
Venture Capital
 HSMN NewsFeed - 4 Sep 2007
ConjuChem Appoints Vice President, General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Aug 2007
Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jul 2007
Gene Logic Recruits Pharmaceutical Executive as Senior Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jul 2007
EyeGate Pharma Announces Executive Appointments
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 16 Jul 2007
Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jul 2007
VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Study Shows VELCADE(R) Plus DOXIL(R) Improves Survival in Previously Treated Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves Event-Free Survival and Complete Response Rate in Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2007
Millennium Appoints Three New Members to Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2007
Tempo Pharmaceuticals Closes $12.1 Million in Series A Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 May 2007
U.S. FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 1 May 2007
Robert G. Pietrusko Joins ViroPharma as Vice President of Global Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 May 2007
ActivBiotics, Inc. Appoints Steven C. Gilman Chairman and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2007
Advancis Pharmaceutical Appoints New Board Member
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Apr 2007
Millennium Discovers Biomarkers Potentially Predictive of Response to VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
Synta Pharmaceuticals Corp. Strengthens Oncology Clinical and Commercial Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2007
Trellis Bioscience Names Bruce Keyt, Ph.D. as Chief Technology Officer and Vice President of Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Mar 2007
Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2007
Vidacare(R) Announces Sales and Marketing Leader for New Hematology/Oncology Business Unit
Devices Personnel
 HSMN NewsFeed - 23 Jan 2007
Synta Pharmaceuticals Corp. Announces Additions to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2007
Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2007
Kenneth M. Bate Named CEO of NitroMed
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2007
Proteolix Elects Dr. Michael Kauffman Chairman of the Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Jan 2007
Napo Pharmaceuticals, Inc. Appoints Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2007
Avalon Pharmaceuticals Names Clinical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2007
Kosan Appoints Jane Green as Vice President, Corporate Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Dec 2006
ImmunoGen, Inc. Announces that sanofi-aventis Has Entered into an Option Agreement for Expanded Access to the Company's TAP Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 20 Dec 2006
Curis Announces Key Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Dec 2006
Kosan Announces License of Motilin Agonist Program to Pfizer
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Dec 2006
Altus Pharmaceuticals Appoints Bruce A. Leicher General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
VELCADE(R) (bortezomib) for Injection Incorporated Into NCCN(R) Clinical Practice Guidelines for Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Positive Results from Combination Trials Build on VELCADE(R) (Bortezomib) for Injection Proven Single-Agent Strength in Relapsed Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Multiple Myeloma Patients Respond to Retreatment with VELCADE(R) (Bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2006
VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near Complete Response Rate in Preliminary Data From Phase III Front-Line Multiple Myeloma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Dec 2006
Allergan Announces New Board Member; Dr. Deborah Dunsire Appointed
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Nov 2006
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2006
Bayhill Therapeutics Names Robert S. King Vice President of Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2006
Millennium Issues Statement Regarding AnorMED Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Oct 2006
AnorMED has determined Genzyme's offer is a 'superior proposal'
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Oct 2006
Genzyme Announces Proposal to Increase Its Offer to Acquire AnorMED to $13.50 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Oct 2006
Archemix Strengthens Management With Appointment of James Gilbert, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Sep 2006
Alnylam Announces Management Transition Plan in Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Sep 2006
Heartscape Technologies Appoints Arthur Hiller, former Millennium Head of Cardiovascular Business, as CEO and Director
Devices Cardiology
 HSMN NewsFeed - 11 Jul 2006
ImmunoGen, Inc. Grants Biotest AG Rights to Use ImmunoGen TAP Technology to Develop Novel Anticancer Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 May 2006
Archemix Corp. Strengthens its Board of Directors Adding Alnylam President and CEO, John Maraganore, Ph.D.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 May 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 May 2006
ImmunoGen, Inc. to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 194

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 194 additional stories matching:
Millennium Pharmaceuticals
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.